Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Equillium Inc (NQ: EQ )

0.7000 -0.0200 (-2.78%)
Streaming Delayed Price Updated: 9:35 AM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Equillium Inc

< Previous 1 2 3 4 5 6 Next >
Equillium to Present at the SVB Leerink Virtual Global Healthcare Conference
From Equillium, Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Mustang Bio (NASDAQ:MBIO) shares ... 
Via Benzinga
Equillium Announces Multiple Abstracts Accepted for Presentation at the Transplantation & Cellular Meetings of ASTCT and CIBMTR
From Equillium, Inc.
Via Business Wire
Equillium to Present at the H.C. Wainwright Virtual BioConnect Conference
From Equillium, Inc.
Via Business Wire
10 Biggest Price Target Changes For Wednesday
UBS cut the price target for Adobe Inc. (NASDAQ: ADBE) from $635 to $575. Adobe shares fell 2.3% to $541.06 in pre-market trading. SVB Leerink lowered the price target on... 
Via Benzinga
45 Biggest Movers From Yesterday
Gainers ATA Creativity Global (NASDAQ: AACG) gained 114.3% to close at $2.55. Hoth Therapeutics, Inc. (NASDAQ: HOTH) surged 85.7% to settle at $1.30 after the company announced... 
Via Benzinga
Equillium Announces Publication of Data in the Journal of Clinical Investigation Highlighting the Importance of the CD6-ALCAM Pathway in the Pathogenesis of Lupus Nephritis
From Equillium, Inc.
Via Business Wire
Equillium To Reassess Potential For Its Asthma Trials
Equillium Inc's (NASDAQ: EQ) Phase 1b EQUIP study of itolizumab in patients with uncontrolled asthma met its primary objective. The data demonstrated an on-target... 
Via Benzinga
Equillium Announces Data from Phase 1b EQUIP Study in Patients with Uncontrolled Asthma
From Equillium, Inc.
Via Business Wire
Equillium Announces Additional Patient Data at ASH 2021 Demonstrating Continued Positive and Durable Clinical Responses in Acute Graft-Versus-Host Disease Patients Treated with Itolizumab
From Equillium, Inc.
Via Business Wire
Equillium Reports Third Quarter 2021 Financial Results and Provides Clinical Development Updates
From Equillium, Inc.
Via Business Wire
Equillium to Present at Two Upcoming Investor Conferences
From Equillium, Inc.
Via Business Wire
Equillium Presents Clinical Data from EQUALISE Phase 1b Study in Lupus Patients at the American Society of Nephrology Annual Meeting
From Equillium, Inc.
Via Business Wire
Equillium Presents Interim Safety Data from First Cohort of Asthma Patients in Phase 1b EQUIP Study at the American College of Allergy, Asthma & Immunology Meeting
From Equillium, Inc.
Via Business Wire
Equillium Announces Two Abstracts Accepted for Presentation at the 63rd ASH Annual Meeting and Exposition
From Equillium, Inc.
Via Business Wire
Equillium Reveals Early Safety Data For Itolizumab In Lupus Patients
Equillium Inc (NASDAQ: EQ) announced interim data from the Type A portion of the Phase 1b EQUALISE study in systemic lupus erythematosus (SLE) patients. Data were... 
Via Benzinga
Equillium Announces Interim Safety Data and Reduction in Proteinuria for Lupus Patients Treated with Itolizumab in the EQUALISE Study Presented at the ACR Annual Meeting
From Equillium, Inc.
Via Business Wire
Equillium Announces Two Abstracts Accepted for Presentation at the Upcoming Virtual 2021 American Society of Nephrology Annual Meeting
From Equillium, Inc.
Via Business Wire
Equillium Announces Multiple Abstracts Accepted for Presentation at ACR Convergence 2021
From Equillium, Inc.
Via Business Wire
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
Via Benzinga
Equillium to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference
From Equillium, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For September 15, 2021
Upgrades For Alcoa Corp (NYSE: 
Via Benzinga
Equillium to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
From Equillium, Inc.
Via Business Wire
60 Biggest Movers From Yesterday
Gainers Trillium Therapeutics Inc. (NASDAQ: TRIL) shares jumped 188.8% to close at $17.59 on Monday after the company agreed to be acquired by Pfizer for $18.50 per share,... 
Via Benzinga
Equillium's Itolizumab Reduces Urine Protein In Lupus Patients
Equillium Inc (NASDAQ: EQ) announced additional data from the Type A portion of the EQUALISE Phase 1b study of itolizumab in systemic lupus erythematosus (SLE) and... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Hims & Hers Health (NYSE:HIMS)... 
Via Benzinga
Equillium Announces Update to EQUALISE Study of Itolizumab in Patients with Systemic Lupus Erythematosus and Lupus Nephritis
From Equillium, Inc.
Via Business Wire
Equillium Reports Second Quarter 2021 Financial Results and Provides Clinical Development Update
From Equillium, Inc.
Via Business Wire
Equillium to Present at the BTIG Virtual Biotechnology Conference
From Equillium, Inc.
Via Business Wire
Equillium's Single Phase 3 Study In aGVHD To Support US Filing Of Itolizumab
Equillium Inc (NASDAQ: EQ) completed an End-of-Phase 1 meeting with the FDA, confirming to advance itolizumab into a single Phase 3 pivotal study in first-line... 
Via Benzinga
Exposures Product Safety
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.